Skip to main content
Cardiogeni Plc logo

Cardiogeni Plc — Investor Relations & Filings

ISIN · GB00BTBLFC12 LEI · 9845000F8F59ATZD8F92 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 23 across all filing types
Latest filing 2025-07-02 Regulatory Filings
Country GB United Kingdom
Listing Aquis Stock Exchange

About Cardiogeni Plc

https://cardiogeni.com/

Cardiogeni Plc is a clinical-stage biotechnology company specializing in the development of regenerative medicines for the treatment of heart failure. Founded by Nobel Laureate Sir Martin Evans, the company focuses on creating novel therapies to address life-threatening cardiovascular diseases. Cardiogeni aims to become a market leader in heart failure regeneration by advancing its product pipeline, which includes candidates like heartcel, through clinical development and commercialization.

Recent filings

Filing Released Lang Actions
Appointment of corporate broker
Regulatory Filings Classification · 100% confidence The document is identified by the header "RNS Number : 2844P" and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content announces the "Appointment of Corporate Broker." This type of announcement, which details a change in corporate advisory/brokerage relationships, is a general regulatory disclosure that does not fit into specific financial reporting categories (like 10-K, ER, or IR). Since it is a general regulatory announcement provided via RNS, and it is not a specific report type, the most appropriate classification is the general regulatory filing category.
2025-07-02 English
Formation of UAE joint venture company
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via RNS (Regulatory News Service) regarding the formation of a joint venture in the UAE. It does not constitute a full report, financial statement, or specific regulatory filing like a 10-K or proxy statement. As it is a general corporate announcement regarding business operations and strategic partnerships, it falls under the 'Regulatory Filings' (RNS) category.
2025-06-05 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 100% confidence The document is a standard TR-1 form, which is the regulatory notification used in the UK for major shareholding disclosures. It explicitly details the identity of the issuer (Cardiogeni PLC), the person subject to the notification (Ajan Reginald), and the percentage of voting rights held (21.17%). This fits the definition of a Major Shareholding Notification (MRQ).
2025-06-03 English
£650,000 Placing at 17.3p per share
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Cardiogeni PLC regarding a new share placing to raise £650,000. It details the number of shares being issued, the price per share, the expected admission date to the AQSE Growth Market, and the resulting total voting rights. This falls under the category of a share issue or capital change announcement.
2025-05-22 English
Update on JV including £20m Funding
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Cardiogeni PLC regarding a progress update on a joint venture and associated £20M funding. It details the principal transaction terms of the agreement. While it mentions funding, it is a corporate announcement of a strategic partnership/financing deal rather than a formal capital raise document or a periodic financial report. Given the nature of the announcement regarding a business development/financing update, it fits best under the 'Capital/Financing Update' category.
2025-04-01 English
Director’s Dealings
Director's Dealing Classification · 100% confidence The document is an official notification of a share purchase by an executive (Darrin Disley, Executive Chairman) of Cardiogeni PLC. It explicitly follows the format for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR), which is the standard regulatory requirement for reporting insider trades. This falls directly under the 'Director's Dealing' category.
2025-02-28 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.